A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder Inhalers
NCT00867282 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2009-07-28
Summary
The purpose of this study is to investigate the time course of PF-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.
Conditions
- Pharmacokinetics
Interventions
- DRUG
-
Treatment A
PF-00241939 750ug using inhaler A
- DRUG
-
Treatment B
PF-00241939 750ug using inhaler B
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 21 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-06-30
- Primary Completion
- 2009-07-31
- Completion
- 2009-07-31
Countries
- Singapore
Study Locations
More Related Trials
-
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
NCT00769119 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma
NCT04576325 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers
NCT01364519 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects
NCT01762878 ·Status: COMPLETED ·Phase: PHASE1
-
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
NCT04313023 ·Status: COMPLETED ·Phase: PHASE2
-
The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
NCT04312997 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection
NCT05616221 ·Status: COMPLETED ·Phase: PHASE2
-
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
NCT05628740 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers
NCT02928354 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome
NCT05279352 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects
NCT02124278 ·Status: COMPLETED ·Phase: PHASE1
-
The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases
NCT06252454 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers
NCT03691584 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers
NCT01690949 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function
NCT05625347 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers
NCT01818024 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria
NCT03219164 ·Status: TERMINATED ·Phase: PHASE3
-
Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis
NCT03903913 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153
NCT02517359 ·Status: TERMINATED ·Phase: PHASE1
-
To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
NCT02679729 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
NCT04720443 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis
NCT07061925 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate
NCT02883439 ·Status: WITHDRAWN ·Phase: NA
-
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
NCT03832946 ·Status: COMPLETED ·Phase: PHASE2